Combining these timing results with recent clinical trial results and what is known about tau spread and clinical symptoms suggests that this time window between p-tau217 + and inferior temporal tau positivity is likely highly important for delaying or potentially halting tau progression and thereby downstream cognitive decline and clinical impairment. The gene discussed is MAPT; the disease is Mental deterioration.